[Recent Progresses of Autoimmune Hemolytic Anemia]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2016 Dec 21

PMID 27995893

Authors

Q Y Gao

F K Zhang

Affiliations

Soon will be listed here.

References

Barker R, Hall A, Standen G, Jones J, Elson C . Identification of T-cell epitopes on the Rhesus polypeptides in autoimmune hemolytic anemia. Blood. 1997; 90(7):2701-15. View

Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet A . Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2014; 14(4):304-13. DOI: 10.1016/j.autrev.2014.11.014. View

Berentsen S, Ulvestad E, Gjertsen B, Hjorth-Hansen H, Langholm R, Knutsen H . Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103(8):2925-8. DOI: 10.1182/blood-2003-10-3597. View

Hall A, Ward F, Vickers M, Urbaniak S, Barker R . Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood. 2002; 100(13):4529-36. DOI: 10.1182/blood-2002-05-1383. View

Bass G, Tuscano E, Tuscano J . Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014; 13(4-5):560-4. DOI: 10.1016/j.autrev.2013.11.010. View

Fagiolo E . Immunological tolerance loss vs. erythrocyte self antigens and cytokine network disregulation in autoimmune hemolytic anaemia. Autoimmun Rev. 2004; 3(2):53-9. DOI: 10.1016/S1568-9972(03)00085-5. View

Risitano A, Ricklin D, Huang Y, Reis E, Chen H, Ricci P . Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014; 123(13):2094-101. PMC: 3968392. DOI: 10.1182/blood-2013-11-536573. View

Birgens H, Frederiksen H, Hasselbalch H, Rasmussen I, Nielsen O, Kjeldsen L . A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013; 163(3):393-9. DOI: 10.1111/bjh.12541. View

Michel M . Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol. 2011; 4(6):607-18. DOI: 10.1586/ehm.11.60. View

10.

Segel G, Lichtman M . Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review. Blood Cells Mol Dis. 2014; 52(4):152-60. DOI: 10.1016/j.bcmd.2013.12.003. View

11.

Berentsen S, Randen U, Vagan A, Hjorth-Hansen H, Vik A, Dalgaard J . High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010; 116(17):3180-4. DOI: 10.1182/blood-2010-06-288647. View

12.

Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W . Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006; 91(4):460-6. View

13.

Sokol R, Booker D, Stamps R, Booth J, Hook V . IgA red cell autoantibodies and autoimmune hemolysis. Transfusion. 1997; 37(2):175-81. DOI: 10.1046/j.1537-2995.1997.37297203520.x. View

14.

Takahashi H, Tanaka F, Sakuma H, Sato M, Inaba S, Kai S . Fatal warm autoimmune hemolytic anemia in a child due to IgM-type autoantibodies. Pediatr Int. 2016; 58(8):744-6. DOI: 10.1111/ped.12931. View

15.

Barcellini W . Current treatment strategies in autoimmune hemolytic disorders. Expert Rev Hematol. 2015; 8(5):681-91. DOI: 10.1586/17474086.2015.1073105. View

16.

Kamesaki T, Toyotsuji T, Kajii E . Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia: a study of 154 cases. Am J Hematol. 2012; 88(2):93-6. DOI: 10.1002/ajh.23356. View

17.

Mehta B, Mahadeo K, Zaw R, Tang S, Kapoor N, Abdel-Azim H . Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer. 2014; 61(12):2324-5. DOI: 10.1002/pbc.25172. View

18.

Hosoba S, Jaye D, Cohen C, Roback J, Waller E . Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2014; 55(2):259-64. PMC: 4342762. DOI: 10.1111/trf.12815. View

19.

Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera-Garza J, Cantu-Rodriguez O, Gutierrez-Aguirre C . Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010; 116(23):4783-5. DOI: 10.1182/blood-2010-06-291831. View

20.

Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E . Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014; 124(19):2930-6. DOI: 10.1182/blood-2014-06-583021. View